ArticlesThe art of communication for leaders: the essence of effective leadership
ArticlesGenAI - reluctance versus opportunity: What do Romanian company leaders expect?
InterviewsHow do we evaluate shares in 2024? Opportunities vs. risks
InterviewsStrauss Romania: Evolving the consumers coffee experience is crucial
InterviewsA long term partnership is better than the commercial value of a deal
NewsFAST FORWARD. THE ORGANIZATION OF THE FUTURE - 20th EDITION
NewsThe new Lexus LBX, a revolutionary compact crossover, is available in Romania
NewsSchneider Electric announces the winners of the Sustainability Impact Awards 2023 in Romania
A year ago, consensus was that 2013 would be a busy year for acquisitions by big pharma companies as they sought to fi ll their “growth gaps” — the additional revenue they need in order to keep pace with the overall drug market
But things didn’t turn out that way. Big pharma companies executed only a handful of small bolt-on deals, and their share of M&A transactions fell to a new low.
For more information, please read the Romanian version of the article, here, or see the attached EY study.
